Discovery of Encrypted Peptides in a Human Matrix Metallopeptidase

Rosa Gaglione, Martina Schibeci, Elio Piccolo, Rosanna Culurciello, Carla Zannella, Francesca Mensitieri, Fabrizio Dal Piaz, Valeria Cafaro, Anna De Filippis, Elio Pizzo, Eugenio Notomista, Marcelo D. T. Torres, César de la Fuente‐Núñez, Angela ArcielloJACS 2025 · DOI

TL;DR

Researchers have discovered novel antimicrobial peptides (AMPs) hidden within a human protein (MMP-19) that show potent activity against a wide range of bacteria, including drug-resistant strains. These "encrypted peptides" also combat biofilms, fight enveloped viruses, and have a favorable safety profile, offering a promising new avenue for developing anti-infective therapies.

What Problem Does This Paper Address?

The escalating crisis of antibiotic resistance poses a severe threat to global health, with existing treatments becoming increasingly ineffective against multidrug-resistant (MDR) pathogens. While antimicrobial peptides (AMPs) are a promising alternative due to their broad-spectrum activity and unique mechanisms of action, their development is often hampered by issues like cytotoxicity, instability, and high manufacturing costs. This paper addresses the need for new, effective, and safe anti-infective agents by exploring a largely untapped reservoir of potential therapeutics: encrypted peptides within the human proteome. These peptides, normally part of larger, non-immune proteins, can be released through proteolytic processing and exhibit potent bioactivity.

Methods

The study employed a multi-pronged approach:

  • In Silico Prediction: A bioinformatic algorithm was used to scan the human proteome for potential antimicrobial peptides (AMPs) hidden within larger proteins. This algorithm specifically looked for regions with favorable physicochemical properties for antimicrobial activity.
  • Recombinant Production: Identified encrypted peptide sequences from human matrix metallopeptidase-19 (MMP-19) were recombinantly produced in E. coli as fusion proteins with onconase. Acidic cleavage was then used to release the peptides.
  • Antimicrobial Assays: Standard methods like broth microdilution were used to determine Minimum Inhibitory Concentrations (MICs) and Minimum Bactericidal Concentrations (MBCs) against a panel of bacterial strains. Time-kill kinetics were also performed to assess the speed of bacterial eradication.
  • Mechanism of Action Studies:
    • Scanning Electron Microscopy (SEM): Visualized the morphological changes in bacteria upon treatment to understand how the peptides damage cells.
  • Membrane Depolarization Assay: Used a voltage-sensitive dye (DiSC3(5)) to measure the disruption of bacterial cell membranes.
  • Zeta Potential Measurement: Assessed changes in surface charge of bacterial cells upon peptide treatment.
  • Anti-Biofilm Assays: Crystal-violet assays were used to evaluate the peptides' ability to inhibit biofilm attachment, formation, and detachment. Confocal Laser Scanning Microscopy (CLSM) provided 3D reconstructions of biofilms.
  • Antiviral Assays: Plaque reduction assays were used to test the peptides' efficacy against enveloped viruses (HCoV-229E, HSV-1) under various treatment conditions (co-treatment, virus/cell pre-treatment, post-treatment).
  • Biocompatibility and Immunomodulatory Assays:
    • Hemolysis Assay: Measured the release of hemoglobin from sheep red blood cells to assess potential erythrocyte damage.
  • Cytotoxicity Assay (MTT): Evaluated the viability of mammalian cell lines (macrophages, fibroblasts, keratinocytes) upon peptide exposure.
  • Immunomodulation Assays: Assessed the release of nitric oxide (NO), TNF-α, and IL-6 from LPS-stimulated macrophages in the presence of peptides.
  • Resistance Development Assay: Serial passaging of bacteria in the presence of sub-MIC concentrations of peptides and conventional antibiotics was performed to assess the emergence of resistance.
  • In Vivo Efficacy: A murine skin abscess model was used to evaluate the anti-infective potential of the lead peptides.
  • D-Amino Acid Analog Synthesis: A fully D-enantiomeric analog of the lead peptide was synthesized to assess its stability and efficacy.

Datasets

Not explicitly discussed in terms of training or evaluation datasets in the context of machine learning models. The study utilized a panel of 18 bacterial strains, including Gram-positive, Gram-negative, antibiotic-resistant, and clinical isolates, for antimicrobial testing. Several viral models (HCoV-229E, HSV-1, CVB3) were used for antiviral assays. Mammalian cell lines and sheep red blood cells were used for safety and immunomodulatory assessments. A murine skin abscess model was used for in vivo evaluation.

Key Insights and Ideas

  • Proteome Mining for Therapeutics: The study demonstrates that the human proteome, beyond known immune proteins, is a rich source of "encrypted" antimicrobial peptides with significant therapeutic potential. This opens up a vast, underexplored landscape for drug discovery.
  • MMP-19 as a Source of AMPs: Matrix metallopeptidase-19 (MMP-19), traditionally known for its role in extracellular matrix remodeling, was identified as a source of potent antimicrobial peptides. This highlights how proteins with non-immune functions can harbor hidden bioactive fragments.
  • Membrane Disruption as a Key Mechanism: The discovered peptides primarily act by depolarizing and permeabilizing bacterial membranes. This mechanism is common among AMPs and is generally less prone to resistance development compared to traditional antibiotics.
  • Broad-Spectrum Activity Beyond Bacteria: The peptides show not only potent activity against a wide range of bacteria (including MDR strains) but also inhibit biofilm formation and eradicate preformed biofilms. Furthermore, they exhibit selective antiviral activity against enveloped viruses.
  • Favorable Safety Profile: The peptides demonstrate negligible hemolysis and cytotoxicity towards mammalian cells, a crucial advantage for therapeutic development. They also possess immunomodulatory properties, specifically reducing inflammation induced by LPS.
  • Synergy with Existing Antibiotics: The peptides show synergistic or additive effects when combined with last-line antibiotics like colistin and polymyxin B, potentially allowing for lower antibiotic doses and combating resistance.
  • Resistance-Evading Potential: Serial passaging experiments showed no emergence of resistance to the identified peptides, contrasting sharply with the rapid resistance development observed with ciprofloxacin.
  • D-Amino Acid Analogs Enhance Stability: Synthesizing a D-amino acid analog of the lead peptide maintained its antimicrobial activity and cytocompatibility while significantly improving proteolytic stability, a key factor for in vivo efficacy.

Key Results

  • Discovery of Three Encrypted Peptides: Three antimicrobial encrypted peptides (EPs) were identified from human MMP-19: r(P)YLL19 (residues 1-19), r(P)YLL33 (residues 1-33), and r(P)PRT33 (residues 247-279).
  • Potent Broad-Spectrum Antimicrobial Activity: The peptides exhibited potent activity against Gram-positive and Gram-negative bacteria, including clinical and MDR strains, with MICs generally in the low micromolar range.
  • Effective Biofilm Control: The peptides inhibited biofilm attachment and formation, and showed some efficacy in eradicating preformed biofilms.
  • Selective Antiviral Activity: r(P)YLL19 and r(P)YLL33 showed significant antiviral activity against enveloped viruses (HCoV-229E, HSV-1), particularly when applied before or during viral exposure.
  • Low Cytotoxicity and Hemolysis: Peptides displayed minimal hemolysis (<5% at 100 µM) and maintained >90% cell viability in macrophage assays.
  • Immunomodulatory Effects: Peptides significantly reduced LPS-induced NO, TNF-α, and IL-6 release from macrophages.
  • No Resistance Emergence: Serial passaging for 21 days did not lead to increased MICs for the peptides, unlike ciprofloxacin.
  • In Vivo Efficacy: The lead peptide r(P)YLL19 and its D-amino acid analog D(P)YLL19 significantly reduced bacterial burden in a murine skin abscess model, comparable to polymyxin B.
  • D(P)YLL19 Superior Stability: The D-amino acid analog D(P)YLL19 showed enhanced proteolytic stability while retaining potent antimicrobial activity and a favorable safety profile.

Limitations and Future Work

  • Limited Viral Spectrum: While effective against enveloped viruses, the peptides did not inhibit the nonenveloped CVB3, suggesting their antiviral mechanism is specific to viral envelopes.
  • Further In Vivo Studies: While promising, the in vivo study was limited to a single bacterial species (A. baumannii) and a specific infection model. Future work should explore efficacy against a broader range of pathogens and in different infection models.
  • Sex-Related Differences: The study used female mice for in vivo experiments and acknowledges that sex can influence healing and antimicrobial outcomes, suggesting future studies should include both sexes.
  • Proteome Mining Expansion: The authors suggest that integrating computational design, proteome mining, and D-amino acid engineering can accelerate the development of next-generation AMPs. This implies further exploration of other human proteins for encrypted bioactive sequences.
  • Therapeutic Development: The findings underscore the potential of these peptides as standalone agents or in combination therapies, paving the way for their further development into clinical anti-infective drugs.

Summary updated

Abstract

The human proteome represents a vast, largely untapped source of encrypted bioactive peptides with therapeutic potential. Here, we report the discovery and functional characterization of three antimicrobial encrypted peptides (EPs) derived from human matrix metallopeptidase-19 (residues 1-19, 1-33, and 247-279). These peptides exhibit potent, broad-spectrum activity against Gram-positive and Gram-negative bacteria, including clinical isolates and multidrug-resistant strains. Mechanistic studies reveal membrane depolarization and permeabilization as the primary mechanism of action. The peptides also inhibit biofilm formation, eradicate preformed biofilms, and exhibit selective antiviral activity against enveloped viruses. Importantly, they display negligible hemolysis and cytotoxicity toward mammalian cells while modulating inflammation through LPS neutralization. Synergy assays reveal synergistic or additive interactions with last-line antibiotics, and no resistance emerged after serial bacterial passaging. A fully d-amino acid analog of the lead peptide retained activity and exhibited cytocompatibility and <i>in vivo</i> efficacy in a murine skin infection model. These findings underscore the therapeutic promise of human protein-derived encrypted peptides and highlight proteome mining as a viable strategy for identifying host-compatible anti-infectives.
BibTeX
@inproceedings{gaglione2025discovery,
  author = {Rosa Gaglione and Martina Schibeci and Elio Piccolo and Rosanna Culurciello and Carla Zannella and Francesca Mensitieri and Fabrizio Dal Piaz and Valeria Cafaro and Anna De Filippis and Elio Pizzo and Eugenio Notomista and Marcelo D. T. Torres and César de la Fuente‐Núñez and Angela Arciello},
  title = {{Discovery of Encrypted Peptides in a Human Matrix Metallopeptidase}},
  booktitle = {JACS},
  year = {2025},
  doi = {10.1021/jacsau.5c00947},
}
Figure